NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used
admin 20th July 2018 Uncategorised 0It hasn’t been an easy couple of months for AstraZeneca’s new respiratory med Fasenra when it comes to challenging GlaxoSmithKline’s Nucala. And in England, that ambition just took another hit.
More: NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used
Source: fierce